Lipoprotein Lipase Deficiency versus alternative aetiologies
Research type
Research Study
Full title
A study of the differences in natural history of patients with hypertriglyceridaemia caused by Lipoprotein Lipase Deficiency (LpLD) compared to those with hypertriglyceridaemia of alternative aetiologies
IRAS ID
229448
Contact name
Handrean Soran
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 6 days
Research summary
The enzyme Lipoprotein lipase (LpL) is essential in breaking down fats in the body so they can be utilised. Lack of the enzyme results in accumulation of unprocessed fats that eventually will damage the body. Fats in the body are measured as triglycerides. Lipoprotein lipase deficiency (LpLD) is a hereditary condition and patients with the condition often present with high levels of triglycerides and acute inflammation of the pancreas (pancreatitis). LpLD is a rare disorder and there is limited knowledge about it. We aim to look at the natural history of patients with confirmed LpLD mutation and compare it with patients with raised triglycerides caused by mutations other than LpLD that also result in reduced LpL activity and patients with raised levels of triglycerides in whom no mutation can be identified.
We will use a database of a previous pilot study in Manchester Royal Infirmary of patients with raised triglycerides levels to look for eligible subjects. The study is non-interventional and there are no study procedures that involve the subjects. All we ask is for suitable subjects to consent to having their medical records reviewed by the research team.REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
18/NW/0068
Date of REC Opinion
17 Jan 2018
REC opinion
Favourable Opinion